(Total Views: 735)
Posted On: 03/26/2024 5:02:35 PM
Post# of 148870
The relationship between the CCL5/CCR5 pathway and fat deposition keeps getting clearer and is right there for all of PhRMA and BioTech to see. I can’t help but think that MASH partnership discussions have to be ongoing. The Holds have been lifted, CA seems to be happy with his fundraising accomplishments. Papers are being published. Protocols being initiated.
MASH is the next Holy Grail of Liver (Read: Metabolism). The HCV bidding wars were off the charts after VRUS-7977 (Pharmasset) showed great promise in phase ii. Those people in Princeton had the Golden Egg. An even bigger egg hides in Vancouver; I don’t think for very long though.
If Dr Jay doesn’t know who the Big Players are, he knows someone who does. I think those NDA’s are working extremely well.
https://pubmed.ncbi.nlm.nih.gov/38497114/
MASH is the next Holy Grail of Liver (Read: Metabolism). The HCV bidding wars were off the charts after VRUS-7977 (Pharmasset) showed great promise in phase ii. Those people in Princeton had the Golden Egg. An even bigger egg hides in Vancouver; I don’t think for very long though.
If Dr Jay doesn’t know who the Big Players are, he knows someone who does. I think those NDA’s are working extremely well.
https://pubmed.ncbi.nlm.nih.gov/38497114/
(19)
(0)Scroll down for more posts ▼
